Canoga Perkins Announces Breakthrough Private 5G Transport Solution Enabling Time Sensitive Networking (TSN)
19.2.2025 07:00:00 CET | Business Wire | Press release
SyncMetra® 100 is a software-defined, IT-operated 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for industrial automation, enterprise AI, and AR/VR applications.
Network connectivity solutions provider, Canoga Perkins today announced that it has begun shipping evaluation units for its SyncMetra 100 transport solution, purpose-built to simplify the deployment, configuration, management, and expansion of low latency private 5G networks for industrial automation including TSN, enterprise AI, and AR/VR applications.
In addition, the company announced its upcoming presence at Mobile World Congress in Barcelona, March 3-6 (Hall 7 Stand 7C3Ex) and at Hannover Messe, March 31-April 4 where it will be demonstrating the SyncMetra solution.
"As advancements in AI, automation and IoT accelerate the proliferation of use cases, the market has been constrained to deploy deterministic wireless networks,” said Malik Arshad, President of Canoga Perkins. “We anticipated this gap and purpose-built SyncMetra to simplify the deployment, configuration, management, and expansion of private 5G networks to open new revenue streams for network owners and their system integrators, VARs and mobile network specialists.”
According to the company, with SyncMetra, IT teams can deploy private 5G networks as easily as Wi-Fi without over-reliance on telco expertise or cost-prohibitive infrastructure unlocking some of the market’s most powerful and promising emerging technologies including AI/ML, IoT, robotics, cloud computing, and edge data inference.
Key Features
The SyncMetrasuite of products introduces new capabilities enabling a programmable, expandable and more affordable alternative to current wireless technologies:
- Deterministic networking supporting real-time communication guaranteed Quality of Service (QoS)
- Ultra-reliable low-latency communications (URLLC), and precise packet delivery
- Software-defined and cloud-managed with centralized orchestration via SyncMetra ManagerTM (SMM)
- Seamless integration with existing IT infrastructure, reducing deployment complexity
- Mission-critical security with complete visibility and programmability
- Expandable architecture that allows businesses to scale as needed
Inquiries related to demonstrations and evaluation units are to be directed to www.canogaperkins.net/contact-2.
About Canoga Perkins
Founded in 1963, privately held Canoga Perkins has a long history of providing mission-critical, secure communications to service providers, the military, government agencies, and utilities. With more than 150,000 active network elements operating in Tier 1 service provider networks, Canoga Perkins is differentiated by the telco reliability of its products and its ability to anticipate and nimbly act on emerging IT trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218480924/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom